Rainwater Prizes Fuel New Hope in Fight Against Brain Disease

FORT WORTH, TX – February 05, 2026 – In a significant boost for neurodegenerative research, the Rainwater Charitable Foundation (RCF) today announced the recipients of its 2026 Rainwater Prizes, awarding a total of $600,000 to three scientists whose work is forging new paths in the understanding and treatment of primary tauopathies. These devastating brain disorders, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), currently have no disease-modifying treatments, leaving patients and families with few options.

The announcement honors a duo from Mayo Clinic Florida, Dr. Dennis W. Dickson and Dr. Melissa E. Murray, with the $400,000 Prize for Outstanding Innovation in Neurodegenerative Research. Dr. Marc Aurel Busche, from the University of Basel and the UK Dementia Research Institute, receives the $200,000 Prize for an Innovative Early-Career Scientist. The awards recognize critical advancements that bring the field closer to developing therapies for diseases linked to the abnormal accumulation of tau protein in the brain.

"This year's Rainwater Prize recipients are changing how the field understands and can ultimately treat tau-associated neurodegenerative diseases," said Jeremy Smith, president of the Rainwater Charitable Foundation. "Their work advances insight into tau biology and brings us closer to the day when patients and families affected by PSP, CBD, and related disorders have real therapeutic options."

Unlocking the Secrets of Tau

The work of the prize-winners represents a multi-pronged attack on tauopathies. Drs. Dickson and Murray are celebrated for their monumental collaborative efforts that have provided groundbreaking insights into the fundamental mechanisms of these diseases.

Together, they direct the world's largest brain banks focused on tauopathies, a critical resource containing over 11,000 brain samples. This vast repository allows researchers to study the disease at an unprecedented scale, supporting the development of personalized therapeutic strategies. Dr. Dickson, a renowned neuropathologist, has reshaped the understanding of tau-related diseases by discovering genetic mutations linked to frontotemporal dementia (FTD) and establishing more accurate diagnostic criteria for CBD. Dr. Murray's Translational Neuropathology Lab complements this work by applying cutting-edge digital pathology and imaging techniques to better understand the link between brain pathology, neuroimaging, and plasma biomarkers.

Their combined approach has successfully identified distinct patterns of tau distribution in the brain, enabling more accurate diagnoses and earlier detection of disease progression.

"I am thrilled to receive this award for our comprehensive neuropathology and biomarker efforts in the field of neurodegenerative disease alongside Dr. Dickson," said Dr. Murray. "As many tau-driven disorders such as PSP, FTD, and CBD remain understudied, the RCF's commitment to initiatives like the Rainwater Prize is essential in accelerating future therapeutic innovations where there are critical gaps."

Meanwhile, Dr. Busche is being recognized for a pivotal discovery that offers a new window of opportunity for intervention. His research identified soluble, high-molecular-weight (HMW) tau as a primary driver of neuronal dysfunction before the irreversible death of brain cells. This suggests that some symptoms of these devastating diseases may stem from a potentially reversible process, opening the door for therapies that could restore neuronal function rather than just slowing cell death.

"Neurodegenerative disease research is moving rapidly, as we identify more diagnostic markers and shed new light on the biological drivers of these diseases," Dr. Busche stated. "It is an honor to be recognized by the RCF, and my lab and I look forward to establishing an open data platform linking different tau species characteristics with their effects on brain activity to accelerate collective progress toward meaningful treatments."

The Power of Purpose-Driven Philanthropy

The Rainwater Charitable Foundation's central role in this field is deeply personal. The foundation was created in the early 1990s by the late investor and philanthropist Richard E. Rainwater. After his own diagnosis in 2009 with Progressive Supranuclear Palsy, the foundation's mission expanded dramatically to accelerate the development of diagnostics and treatments for tau-related disorders.

With over $165 million invested in medical research to date, RCF has become one of the largest independent funders in the space, helping to advance eight different treatments into human trials. Its strategy focuses on funding high-risk, high-reward research that may be overlooked by traditional sources, creating programs like the Tau Consortium and the Tauopathy Challenge Workshop to foster collaboration and attract new talent to the field.

This approach is critical for diseases like PSP and CBD, where the complex pathophysiology and diagnostic challenges have slowed progress. The lack of effective treatments represents a massive unmet need, making the strategic investments of organizations like RCF and their partners, including CurePSP and the Alzheimer's Association, all the more vital.

A Collaborative Path Forward

The dual recognition of established leaders and a rising star highlights a key strategy in the fight against neurodegenerative disease: combining decades of foundational knowledge with fresh, innovative perspectives. The work of Drs. Dickson and Murray provides the deep pathological understanding and resources that enable new theories, while Dr. Busche's innovative methodologies are creating new paradigms for treatment.

The awardees will be formally honored for their achievements at the 2026 Tau Global Conference in Washington, D.C., this May. The conference is a key nexus for the global scientific community, bringing together top researchers from academia, industry, and government to share findings and forge collaborations. It is at gatherings like these that individual breakthroughs, like those celebrated by the Rainwater Prize, are shared, debated, and integrated into a collective effort to conquer these challenging diseases. Dr. Busche's plan for an open data platform further embodies this spirit, promising to accelerate progress for the entire research community and, ultimately, for the patients who await a cure.